Mipasetamab is an IgG1κ monoclonal antibody specifically designed to target AXL, a member of the TAM family of receptor tyrosine kinases. This antibody plays a crucial role in the synthesis of ADCT-601 (Mipasetamab uzoptirine), an antibody-drug conjugate (ADC) that selectively binds to the AXL receptor. ADCT-601 demonstrates significant antitumor activity, leveraging the specificity of Mipasetamab to deliver cytotoxic agents directly to AXL-expressing tumor cells, thereby enhancing therapeutic efficacy while minimizing off-target effects. This product is pivotal for research focused on the development of targeted cancer therapies, particularly in studies investigating the role of AXL in cancer progression and resistance mechanisms.
Mipasetamab is an IgG1κ monoclonal antibody specifically designed to target AXL, a member of the TAM family of receptor tyrosine kinases. This antibody plays a crucial role in the synthesis of ADCT-601 (Mipasetamab uzoptirine), an antibody-drug conjugate (ADC) that selectively binds to the AXL receptor. ADCT-601 demonstrates significant antitumor activity, leveraging the specificity of Mipasetamab to deliver cytotoxic agents directly to AXL-expressing tumor cells, thereby enhancing therapeutic efficacy while minimizing off-target effects. This product is pivotal for research focused on the development of targeted cancer therapies, particularly in studies investigating the role of AXL in cancer progression and resistance mechanisms.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
